Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Nutrien Ltd — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B), while Nutrien Ltd trades at $67.48 (market cap $33.31B). The key difference: Nutrien Ltd is far larger — about 5.5× Iovance Biotherapeutics Inc. Common Stock's market cap, and Nutrien Ltd pays a 3.15% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Nutrien Ltd for 59 Days on average.
| IOVA | NTR | |
|---|---|---|
Market Cap | $6.04B | $33.31B |
Volume | 14,805,993 | 1,330,729 |
Sector | Health | Basic Materials |
52-Week High | $14.82 | $83.94 |
52-Week Low | $1.81 | $53.64 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $5.97B | $45.11B |
Dividend Yield | — | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Nutrien (NTR) trades at $69.87, down 0.14% with a bearish technical signal despite positive analyst sentiment. The company shows improving fundamentals with 2025 revenue of $26.89B and net income of $2.27B, representing an 8.44% margin. Recent earnings show mixed results with Q1 2026 beating expectations but Q2 2026 missing estimates. Cash flow trends indicate operational strength with $4.01B from operations in 2025, though net cash flow remains negative. The stock faces headwinds from fertilizer industry challenges but benefits from strong potash demand and cost discipline.
NTR presents a moderate buy opportunity with 60.61% analyst buy ratings and $76.14 consensus price target offering 9% upside. Key catalysts include November 2026 Investor Day and structural gas arbitrage benefits, while risks involve fertilizer price volatility, geopolitical supply disruptions, and sulfur cost pressures. The company's North American nitrogen assets provide competitive advantage, but investors should monitor agricultural cycle trends and input cost management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
